Lipid-based nanoformulations in the treatment of neurological disorders. Pottoo et al. 2020. Drug Metabolism Reviews. 


Neurological disorders such as Parkinson or Alzheimer disease affect millions of people worldwide. The currently available therapies are mostly symptomatic and cannot tackle the origin of the disease. This is due to the blood-brain barrier, a specialized network of endothelial cell layers and other brain cells that prevents solutes in blood from crossing non-selectively into the central nervous system (CNS). This barrier often limits the amount of drug that can reach neuronal tissues and thus, this physiological feature hampers the application of novel treatments for neurological conditions.


Lipid nanoparticles (LNPs) may overcome this challenge, as they can exploit physiological transport mechanisms along the blood-brain barrier to cross it and reach neuronal tissues. Read this review to learn more about how the use of LNPs as carriers for the targeted delivery of drugs to the CNS can improve the treatment of neurological disorders.